Mannkind reports net loss for second quarter
Mannkind reported $2.16 million in revenues Aug. 7, for a net loss of around $35.3 million for its second quarter, and announced the launch of a clinical trial for its inhalable insulin product Afrezza in partnership with One Drop. Revenues came primarily from the Westlake Village biotech company’s product sales, with $615,000 from collaborations and Read More →
Read More →
Sienna stock still soaring after $65 million IPO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Teledyne reports record sales for second quarter
Thousand Oaks-based tech giant Teledyne reported record sales for its second quarter, ended July 2, reaching $671.1 million and net income of $60.1 million, or $1.66 per diluted share. In addition to growth in all its major product lines — particularly its digital imaging segment, which saw an 89.6 percent increase to $188.5 million — Read More →
Read More →Amgen stock drops despite strong earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Sienna stock soars after $65 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals closed with a big gain after it raised $65 million in its initial public offering July 27. Sienna priced the 4.33 million shares it offered at $15. Shares had reached $21 around noon before ending at $19.25, a 28.3 percent premium on its opening price. The company operates in Read More →
Read More →Moorpark company’s medicine bottles target elderly, opioid crisis
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen partnering to develop new drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
2015-2016 Giving Guide
